Business, energy, technology, markets and global industry news from Business News Today

Anixa Biosciences

PharmaDeviceNews Anixa Biosciences
Representative image: Cancer immunotherapy research advances as Anixa Biosciences evaluates its breast cancer vaccine and lira-cel CAR-T therapy in early-stage clinical trials.
Pharma & Biotech

Can Anixa’s breast cancer vaccine and lira-cel CAR-T therapy translate early immune signals into clinical benefit?

Anixa Biosciences has presented completed Phase 1 data for its alpha-lactalbumin breast cancer vaccine and updated survival observations for liraltagene autoleucel in recurrent ovarian cancer. The findings strengthen the biological rationale behind both programmes, but controlled efficacy evidence, biomarker clarity and successful dose optimisation remain essential before either platform can be considered clinically validated.

Read More
Pharma & Biotech

Why Anixa Biosciences’ Phase 2 breast cancer vaccine push matters more than the manufacturing deal itself

Anixa Biosciences is advancing its breast cancer vaccine toward Phase 2 after positive Phase 1 data. Read what this means for oncology watchers.

Read More
Pharma & Biotech

How Anixa’s breast cancer vaccine could change immunoprevention strategies

Anixa Biosciences Inc. has reported final Phase 1 results for its investigational breast cancer vaccine targeting the α-lactalbumin protein, showing that the primary endpoints were met and 74 percent of participants demonstrated protocol-defined immune responses. The data were presented at the 2025 San Antonio Breast Cancer Symposium and build the case for a Phase 2

Read More
Representative image illustrating next-generation cancer vaccine research targeting “retired proteins” like alpha-lactalbumin—reflecting the new wave of immunization strategies explored in our story: “Can cancer vaccines finally deliver on their promise?
Features & Analysis

Why are “retired proteins” the hottest new targets in cancer immunotherapy research?

Few ideas have captivated both the scientific imagination and biotech investment flows quite like the cancer vaccine. For decades, the industry narrative was full of hope—and disappointment. The graveyard of failed trials stretches from Dendreon’s Provenge to once-hyped peptide and dendritic cell platforms. For every announcement of an “immune breakthrough,” there seemed to be a

Read More